Paul Tudor Jones’s Denali Therapeutics DNLI Stock Holding History

Paul Tudor Jones’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05M	Buy	+40,965	New	+$842K	﹤0.01%	2384
2026 Q1	–	Sell	-53,683	Closed	-$886K	–	3756
2025 Q4	$886K	Sell	53,683 -2,685	-5%	-$45.3K	﹤0.01%	2355
2025 Q3	$818K	Buy	56,368 +920	+2%	+$13.2K	﹤0.01%	2398
2025 Q2	$776K	Sell	55,448 -17,149	-24%	-$241K	﹤0.01%	2300
2025 Q1	$987K	Buy	+72,597	New	+$1.39M	﹤0.01%	1824
2024 Q3	–	Sell	-58,523	Closed	-$1.36M	–	2790
2024 Q2	$1.36M	Sell	58,523 -13,128	-18%	-$252K	0.01%	1296
2024 Q1	$1.47M	Buy	+71,651	New	+$1.35M	0.01%	1170
2023 Q4	–	Sell	-42,020	Closed	-$867K	–	2467
2023 Q3	$867K	Buy	+42,020	New	+$1.07M	0.01%	1376
2023 Q2	–	Sell	-55,346	Closed	-$1.27M	–	2543
2023 Q1	$1.27M	Buy	55,346 +5,415	+11%	+$149K	0.02%	1044
2022 Q4	$1.39M	Buy	+49,931	New	+$1.49M	0.03%	862
2022 Q3	–	Sell	-16,464	Closed	-$485K	–	2390
2022 Q2	$485K	Buy	+16,464	New	+$431K	0.01%	1285
2021 Q2	–	Sell	-39,106	Closed	-$2.23M	–	1664
2021 Q1	$2.23M	Buy	+39,106	New	+$2.62M	0.04%	473
2020 Q3	–	Sell	-37,926	Closed	-$917K	–	1345
2020 Q2	$917K	Buy	+37,926	New	+$892K	0.05%	503

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's DNLI Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 40,965 shares worth $1.05M. The stake represents ﹤0.01% of the portfolio and ranks #2384 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in DNLI as recently as Q4 2025.

Paul Tudor Jones first reported a position in DNLI in Q2 2020 and has held it in 13 quarters since. The position peaked at $2.23M in Q1 2021. 290 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Paul Tudor Jones held 40,965 shares of Denali Therapeutics worth $1.05M as of Q2 2026.
Denali Therapeutics was a new Paul Tudor Jones position in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2384 holding.
Paul Tudor Jones first reported a position in Denali Therapeutics in Q2 2020 and has held it in 13 quarters since.
Paul Tudor Jones's Denali Therapeutics position peaked at $2.23M in Q1 2021.
290 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.